Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ASBRON vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Relief of symptoms of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema,Symptomatic relief of productive cough associated with respiratory conditions
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Theophylline is primarily metabolized by cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Guaifenesin is metabolized via oxidation and glucuronidation.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
50-60% bound to albumin and alpha-1-acid glycoprotein
65% bound to albumin
0.3-0.5 L/kg; indicates distribution primarily into extracellular fluid
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral: 40-60%; rectal: 50-70%; inhalation: 10-30%
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
GFR 30-59 m L/min: reduce dose by 25-50%; GFR <30 m L/min: reduce dose by 50% and monitor serum theophylline levels.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B or C: reduce dose by 75% and monitor serum theophylline levels.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Weight-based: 10-16 mg/kg/day theophylline equivalent divided every 6-8 hours; maximum 400 mg/day. Adjust based on serum levels.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Elderly patients: initial dose of 130 mg orally every 8 hours; titrate gradually; monitor serum theophylline levels due to reduced clearance.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
Theophylline has a narrow therapeutic index; serious adverse effects including seizures and arrhythmias can occur at levels close to therapeutic range. Do not exceed recommended doses. Use caution in patients with cardiac or hepatic impairment.
No FDA black box warning.
Theophylline toxicity is dose-related; monitor serum levels. Caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, or cardiovascular disease. Drug interactions with quinolones, macrolides, and cimetidine can increase theophylline levels.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to theophylline or guaifenesin, active peptic ulcer disease, seizure disorders (unless controlled), and severe cardiac arrhythmias.
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid high-fat meals with extended-release formulations as they may alter absorption. Limit caffeine-containing foods/beverages (coffee, tea, chocolate) due to additive CNS stimulation. No significant food interactions with guaifenesin.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no known teratogenicity but may cause fetal tachycardia, jitteriness, or transient neonatal effects (e.g., irritability, vomiting) due to transplacental passage. Guaifenesin: Limited human data; animal studies not indicative of teratogenicity. Overall, Asbron is considered relatively low risk, but non-pharmacologic measures preferred in first trimester.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline is excreted into breast milk with an average milk-to-plasma ratio of 0.67. Maximum milk concentration correlates with maternal serum levels. With typical maternal doses, infant serum levels may reach 2-4 mcg/m L, rarely causing irritability or poor feeding. Guaifenesin is likely minimally transferred. Asbron is considered compatible with breastfeeding; observe infant for signs of theophylline side effects (jitteriness, insomnia).
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Theophylline clearance increases by 20-30% in pregnancy due to increased hepatic metabolism and volume of distribution, particularly in second and third trimesters. Starting doses should be based on non-pregnant recommendations, but maintenance doses may need to be increased by up to 30% to achieve therapeutic levels. Monitor serum levels every 1-2 weeks and adjust dose to maintain trough 5-10 mcg/m L (lower end to minimize fetal exposure). Postpartum, clearance decreases rapidly; reduce dose and monitor levels closely to avoid toxicity.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline has a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L) due to variable metabolism. Guaifenesin is an expectorant but evidence for efficacy is limited. Avoid in patients with active peptic ulcer disease or seizure disorders. Cimetidine, fluoroquinolones, and macrolides increase theophylline levels; smoking and rifampin decrease levels.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take Asbron exactly as prescribed; do not crush or chew extended-release tablets.,Avoid excessive caffeine intake (coffee, tea, cola) as it may increase side effects.,Report symptoms of theophylline toxicity: nausea, vomiting, insomnia, tremors, fast heartbeat.,Do not stop abruptly; dosage tapering may be needed.,Stay hydrated to help guaifenesin work effectively.,Avoid alcohol as it may increase side effects like dizziness.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ASBRON vs AEROLATE, answered by our medical review team.
ASBRON is a Bronchodilator that works by Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ASBRON and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ASBRON is: 1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ASBRON and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ASBRON is classified as Category C. Asbron contains theophylline and guaifenesin. Theophylline: In first trimester, limited data suggest no major teratogenic risk (FDA category C). In second and third trimesters, no . AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.